10x Genomics (TXG) Misses Q4 EPS by $3.64, Revenues Beat; Offers FY21 Revenue Mid-Point Guidance Below Consensus

10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($3.87), $3.64 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $112.2 million versus the consensus estimate of $100.4 million.

Recent Highlights

• Revenue was $298.8 million for the full year and $112.2 million for the fourth quarter of 2020, representing 22% and 49% increases over the corresponding periods of 2019
• 2,412 Chromium instruments sold as of December 31, 2020
• More than 2,200 peer-reviewed publications based on data generated using 10x products
• Operations center in Singapore came online and began consumables manufacturing

GUIDANCE:

10x Genomics sees FY2021 revenue of $480-500 million, versus the consensus of $494.02 million.

2021 Financial Guidance

10x Genomics expects full year 2021 revenue to be in the range of $480 million to $500 million, representing 61% to 67% growth over full year 2020 revenue.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Ennis (EBF) Reports In-Line Q1 EPS